The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tamoxifen Citrate in Patients With Breast Cancer
Official Title: Tamoxifen Metabolism and the Impact of Tamoxifen Dose on the Level of the Active Metabolites in Endocrine Sensitive Breast Cancer Patients
Study ID: NCT00963209
Brief Summary: RATIONALE: Estrogen can promote growth of endocrine sensitive breast cancer cells. Endocrine therapy with tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells. Pharmacokinetics and -genomics can have an impact on the efficacy of the treatment. PURPOSE: This phase III trial is studying blood samples to see if the level of active metabolites of tamoxifen can be improved in patients with breast cancer.
Detailed Description: OBJECTIVES: Primary * To determine how the increase of tamoxifen citrate dose influences the level of its major metabolites in patients with hormone-sensitive breast cancer. Secondary * To characterize the population pharmacokinetic profile * To investigate the role of the other CYPs * To assess the relation between clinical symptoms and CYP2D6 genotypes and/or active metabolites levels * To explore the correlation between genotypes/metabolites levels and clinical outcomes in terms of tumor relapse. * To assess the feasibility, efficacy, and safety of concentration-guided adjustment of tamoxifen citrate dosage. * To conduct other exploratory analysis based on the eventual new data coming up in the future. OUTLINE: Patients receive oral tamoxifen citrate (at a dose of 40 mg/day) daily for 4 months in the absence of disease progression or unacceptable toxicity. Blood samples are collected for PK, genotyping, phenotyping, and further analysis.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hôpitaux Universitaire de Genève, Genève, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Name: Khalil Zaman, MD
Affiliation: Centre Hospitalier Universitaire Vaudois
Role: PRINCIPAL_INVESTIGATOR